Xponance Inc. Trims Stake in Pfizer Inc. $PFE

Xponance Inc. decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 2.8% during the third quarter, Holdings Channel reports. The fund owned 874,577 shares of the biopharmaceutical company’s stock after selling 25,024 shares during the period. Xponance Inc.’s holdings in Pfizer were worth $22,284,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Brighton Jones LLC increased its stake in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC increased its stake in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after purchasing an additional 2,087 shares in the last quarter. United Bank lifted its holdings in shares of Pfizer by 12.4% during the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock valued at $1,408,000 after purchasing an additional 6,415 shares during the last quarter. Waterfront Wealth Inc. boosted its position in shares of Pfizer by 43.3% in the 2nd quarter. Waterfront Wealth Inc. now owns 18,487 shares of the biopharmaceutical company’s stock worth $448,000 after purchasing an additional 5,588 shares in the last quarter. Finally, Flagship Harbor Advisors LLC increased its position in Pfizer by 11.5% during the 2nd quarter. Flagship Harbor Advisors LLC now owns 74,068 shares of the biopharmaceutical company’s stock valued at $1,795,000 after buying an additional 7,668 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on PFE shares. TD Cowen reissued a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $26.00 target price on shares of Pfizer in a report on Wednesday, November 5th. HSBC reiterated a “buy” rating and issued a $29.00 target price on shares of Pfizer in a research note on Wednesday, December 10th. Barclays began coverage on Pfizer in a research report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price objective on the stock. Finally, BMO Capital Markets restated an “outperform” rating on shares of Pfizer in a research note on Wednesday, December 10th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $27.70.

Pfizer Price Performance

PFE stock opened at $27.11 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The company has a market capitalization of $154.14 billion, a PE ratio of 19.93 and a beta of 0.47. The company’s fifty day moving average price is $26.08 and its 200-day moving average price is $25.39. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.94.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The company had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The firm’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same period in the previous year, the business earned $0.63 earnings per share. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.3%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s payout ratio is 126.47%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.